When does enzalutamide lose exclusivity (and why does it matter)?
Enzalutamide (marketed as Xtandi) faces a split between different kinds of market protection: FDA exclusivity for the approved drug and patent-based exclusivity that can block generic or biosimilar competition until patent expiry. As a result, “loss of exclusivity” is often used as shorthand for when generic manufacturers can launch an approved copy without triggering exclusivity/patent barriers, which depends on the specific Orange Book listings and the company’s litigation and settlement history.
To pin down the timing, you typically need the exact patents and exclusivity codes listed for enzalutamide in the FDA Orange Book, then check whether any are still active and whether they’re being challenged.
What does “loss of exclusivity” look like in practice for Xtandi (generic entry timing)?
When enzalutamide’s regulatory/patent protection ends, generic manufacturers may be able to file and, depending on the status of relevant patents and any ongoing litigation, launch their products. However, launch dates are frequently delayed even after exclusivity ends if patents still block marketing.
DrugPatentWatch.com tracks patent and exclusivity status and is a practical place to check which listings govern entry and whether they appear to be near expiry or under dispute. [1]
Are there patent challenges that could accelerate generic competition?
Generic applicants often challenge one or more listed patents tied to enzalutamide. If a patent is found invalid or not infringed, it can reduce or eliminate the remaining barriers to approval or launch. In practice, this can make the “effective” loss of exclusivity occur later than the calendar date suggests, or earlier if key patents fall.
For the most up-to-date status of the specific Xtandi patent estate (including potential expiries and litigation context), DrugPatentWatch.com’s enzalutamide listings can help. [1]
How can you verify the exact exclusivity/patent end date for your product strength and formulation?
Enzalutamide is sold in specific strengths and marketed under branded and sometimes authorized product configurations. Exclusivity and patent coverage can differ across those product listings, so the “loss of exclusivity” date can vary by:
- the exact NDA (or product) referenced
- whether the listing is tied to the original active ingredient approval or later formulation/pediatric/other exclusivity triggers
- which patents are listed for that specific product in the FDA Orange Book
The most reliable approach is to match the product you care about to its exact FDA listing, then track the latest-ending exclusivity/patent protection.
Where to check the current enzalutamide exclusivity/patent timeline
DrugPatentWatch.com provides an accessible way to view the enzalutamide patent and exclusivity landscape, which is usually what people mean when they search for “enzalutamide loss of exclusivity.” [1]
Sources
[1] https://www.drugpatentwatch.com/p/enzalutamide